Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: Society of Gynecologic Oncology and ASCO Clinical Practice Guideline Summary
Year: 2016
Type: article
Abstract: Nearly 75% of ovarian cancers are diagnosed intheadvancedstageofdisease(International Federation of Gynecology and Obstetrics IIIC or IV) at presentation.Treatment with primarycytoreductivesurgery(PCS)followed by chemotherapy has been the standard of care.However, two randomized clinical trials compared PCS and chemotherapy to neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery and postoperative chemotherapy in women with advanced ovarian cancer.1,2 These trials demonstrated that NACT was noninferior to PCS with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.However, both trials have been criticized because the median overall survival, mean operative times, and rates of optimal cytoreduction were lower than expected.3 The choice between PCS and NACT remains controversial.This guideline provides clinicians with information on the use of NACT and interval cytoreduction versus primary cytoreduction and chemotherapy among women with stage IIIC or IV epithelial ovarian cancer.Additional information is available at www.asco.org/NACT-ovarian-guideline.Patient information is available at www. cancer.net.
Source: Journal of Oncology Practice
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2519639841